Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLE: Aflibercept in Wet AMD
NCT02689518Phase 4Completed
- Sponsor
- University of California, San Diego
- Start
- Apr 2014
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by University of California, San Diego. Primary endpoint: Anatomic Response at 12 months. Started Apr 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02689518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689518.